Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

BrainStorm Cell Therapeutics I / Equity Bottom-Up

<ul><li>On July 8, 2024, BrainStorm Cell Therapeutics, Inc. (BCLI) conducted a mid-year conference call to provide an update on the status of the company's NurOwn program.</li><li>During the call, the company reiterated that it is committed to conducting a Phase 3b trial of NurOwn in patients with amyotrophic lateral sclerosis (ALS) to support a potential Biologics License Application (BLA) filing.</li><li>BrainStorm has reached agreement with the FDA on a Special Protocol Assessment (SPA) and the CMC aspects of the upcoming Phase 3b trial.</li></ul>

On July 8, 2024, BrainStorm Cell Therapeutics, Inc. (BCLI) conducted a mid-year conference call to provide an update on the status of the company's NurOwn program.During the call, the company reiterated that it is committed to conducting a Phase 3b trial of NurOwn in patients with amyotrophic lateral sclerosis (ALS) to support a potential Biologics License Application (BLA) filing.BrainStorm has reached agreement with the FDA on a Special Protocol Assessment (SPA) and the CMC aspects of the upcoming Phase 3b trial.

BCLI: Preparing to Initiate Phase 3b Trial of NurOwn  Before End of 2024 